GE HealthCare (GEHC) Reportedly Eyes $1B Sofie Deal. What Would Ownership Add?

GE HealthCare Technologies Inc. (NASDAQ: GEHC ) is reportedly discussing a possible $1 billion acquisition of Sofie Biosciences. Reuters reported the talks on September 13, citing the Financial Times, which attributed them to people familiar with the matter. Reuters could not independently verify the report, and no agreement was confirmed in its coverage.

The strategic question starts with an existing relationship. Under an October 2023 agreement, GE HealthCare Technologies Inc. (NASDAQ:GEHC) licensed global rights to Gallium-68 FAPI-46 and rights outside the United States to Fluorine-18 FAPI-74. Sofie retained U.S. clinical-development and commercialization rights to F-18 FAPI-74.

These investigational radiotracers target fibroblast activation protein, or FAP, for positron emission tomography scans. For GE HealthCare Technologies Inc. (NASDAQ:GEHC), ownership would need to deliver enough additional rights, manufacturing earnings, and operational benefits to justify the reported price.

The retained U.S. rights present a concrete potential addition. If included in a transaction, they would expand the geographic scope of GE HealthCare Technologies Inc. (NASDAQ:GEHC)'s F-18 FAPI-74 interests beyond the published licensing package. That could align development and commercialization decisions across markets.

Sofie also brings an operating manufacturing base. In January, Sofie said seven radiopharmacies were producing F-18 FAPI-74. GE HealthCare Technologies Inc. (NASDAQ:GEHC) could gain greater control over production capacity, supply planning and the economics of manufacturing services. Those capabilities extend beyond access to intellectual property.

The development program has advanced since the original licensing announcement. In February, Sofie announced the first patient dosed in its Phase 3 pancreatic-cancer imaging study, alongside a gastroesophageal-cancer study that had dosed its first patient in December 2025.

For GE HealthCare Technologies Inc. (NASDAQ:GEHC), combining retained rights, development assets and manufacturing operations could strengthen its pharmaceutical diagnostics business. Existing collaboration also provides experience working with the target, potentially helping integration planning.

GE HealthCare Technologies Inc. (NASDAQ:GEHC) already holds substantial licensed rights. Investors should therefore assess the value added by ownership against the alternative of continuing the commercial relationship. Growth already accessible under existing licenses should not be counted again as a new acquisition benefit.